I. Svane

Functional characterization of Foxp3-specific spontaneous immune responses

I. Svane, A. Woetmann, N. Odum, 2013, Leukemia.

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms

H. Hasselbalch, M. Holmström, M. Andersen, 2016, Leukemia.

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

I. Svane, S. K. Larsen, M. Andersen, 2014, Leukemia.

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms

H. Hasselbalch, Ö. Met, P. Straten, 2017, Leukemia.

Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin‐Expressing Cells

I. Svane, O. Met, M. Andersen, 2016, Scandinavian journal of immunology.

The 1170 A–P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag)

P. Straten, R. Andersen, A. Letsch, 2009, Leukemia.

Changes in Peripheral Blood Level of Regulatory T cells in Patients with Malignant Melanoma During Treatment with Dendritic Cell Vaccination and Low‐dose IL‐2

P. thor Straten, M. Andersen, M. Brimnes, 2011, Scandinavian journal of immunology.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy

I. Svane, H. Hasselbalch, Ö. Met, 2018, Leukemia.